Characteristicsa | UC (N = 50) | CD (N = 50) | Controls (N = 100) | p |
---|---|---|---|---|
Age | 31.5 ± 10.1 | 30.5 ± 9.7 | 31.2 ± 9.8 | 0.864 |
Gender | 0.990 | |||
Male | 28 (56.0) | 28 (56.0) | 57 (57.0) | |
Female | 22 (44.0) | 22 (44.0) | 43 (43.0) | |
Cigarette-smokers | 40 (80.0) | 35 (70.0) | 39 (39.0%) | < 0.001 |
Disease duration (years) | 0.314 | |||
≤ 3 | 20 (40.0) | 25 (50.0) | NA | |
> 3 | 30 (60.0) | 25 (50.0) | NA | |
Positive family history | 7 (14.0) | 8 (16.0) | NA | 0.779 |
Hb (mg/dL) | 11.0 ± 3.0 | 10.5 ± 3.5 | NA | 0.682 |
WBC (× 109/L) | 8.1 ± 3.6 | 7.7 ± 3.1 | NA | 0.783 |
ESR (mm/hour) | 54.3 ± 22.5 | 58.8 ± 42.4 | NA | 0.876 |
Disease extension | ||||
Ulcerative proctitis | 20 (40.0) | NA | NA | |
Left-sided colitis | 15 (30.0) | NA | NA | |
Extensive colitis | 15 (30.0) | NA | NA | |
Ileocecal | NA | 43 (86.0) | NA | |
Ileo-colonic | NA | 7 (14.0) | NA | |
Symptoms | ||||
Abdominal/or colon pain | 33 (66.0) | 33 (66.0) | NA | 1.000 |
Diarrhea | 29 (58.0) | 27 (54.0) | NA | 0.840 |
Fever | 22 (44.0) | 27 (54.0) | NA | 0.424 |
Extra-intestinal manifestations | ||||
Aphthous ulcer | 9 (18.0) | 15 (30.0) | NA | 0.241 |
Arthralgia | 34 (68.0) | 38 (72.0) | NA | 0.504 |
Skin ulcer | 7 (14.0) | 3 (6.0) | NA | 0.318 |
Appendectomy | 6 (12.0) | 7 (14.0) | NA | 1.000 |
Bowel stricture | 4 (8.0) | 3 (6.0) | NA | 1.000 |
Colostomy | 5 (10.0) | 6 (12.0) | NA | 1.000 |
Fistula | 10 (20.0) | 6 (12.0) | NA | 0.414 |
Hemorrhoids | 6 (12.0) | 3 (6.0) | NA | 0.487 |
Medication | 0.556 | |||
Protocol A | 14 (28.0) | 12 (24.0) | ||
Protocol B | 12 (24.0) | 8 (16.0) | ||
Protocol C | 11 (22.0) | 11 (22.0) | ||
Protocol D | 13 (26.0) | 19 (38.0) | ||
Adalimumab or infliximab doses | 0.614 | |||
0 | 12 (24.0) | 8 (16.0) | ||
1–10 | 20 (40.0) | 18 (36.0) | ||
11–20 | 13 (26.0) | 18 (36.0) | ||
21–30 | 5 (10.0) | 6 (12.0) |